Bahrain’s National Health Regulatory Authority (NHRA) has approved oral Wegovy (semaglutide) for obesity treatment, expanding access to newer therapeutic options in the kingdom.
According to the Bahrain News Agency, the approval reflects the country’s efforts to strengthen pharmaceutical regulation and keep pace with advances in medical treatment. The authority said the decision supports access to modern medicines under established medical and regulatory standards.
The oral medication entered the Bahraini market in mid-September 2026, making Bahrain the second Gulf Cooperation Council (GCC) country, after the UAE, and the fifth country worldwide to make the treatment available, according to the report.
Click here to join our WhatsApp channel here
Wegovy pills are now available in pharmacies in Bahrain. The NHRA has advised patients to use the medicine according to approved medical instructions and after consulting a healthcare professional to ensure its suitability for their individual health conditions.
The approval expands the range of available treatment options for obesity and related chronic health conditions, as Bahrain continues to align its healthcare services with developments in obesity management.
Also read: ART Fertility Conference Returns to Abu Dhabi for Ninth Edition
